Healthcare 9 August 2025 - 14 February 2026

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding
····

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding

Serve Robotics Inc. shares fell 1.25% to $8.70 Friday, underperforming a record-setting Dow, then ticked up to $8.73 after hours. Volume reached 3.84 million shares, with a market value near $673 million. Investors weighed rapid revenue growth and a new hospital robotics push against funding and execution risks ahead of the Memorial Day market holiday.
May 22, 2026
Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight
···

Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight

The S&P 500 Health Care index rose 1.01% to 1,835.92 on Friday, with Dexcom up 7.6% and Moderna up 5.3% after earnings. Moderna warned of regulatory uncertainty after the FDA refused to review its flu shot. Disc Medicine shares fell 21% after the FDA declined to approve its rare-disease drug. U.S. markets close Monday for Presidents Day; Medtronic reports Tuesday.
February 14, 2026
UnitedHealth (UNH) stock price today: shares rise as healthcare gets a bid, but Medicare Advantage rates still loom
···

UnitedHealth (UNH) stock price today: shares rise as healthcare gets a bid, but Medicare Advantage rates still loom

UnitedHealth shares rose 1.3% to $288.14 in midday New York trading Friday, with nearly 4 million shares changing hands. Managed-care stocks gained despite warnings on Medicare Advantage plan ratings and uncertainty over 2027 reimbursement rates. Humana, Elevance, Cigna, and CVS Health also traded higher. CMS will announce final 2027 Medicare Advantage payment rates by April 6.
February 13, 2026
AbbVie stock jumps as Botox Medicare lawsuit puts Washington back in focus
···

AbbVie stock jumps as Botox Medicare lawsuit puts Washington back in focus

AbbVie shares rose nearly 3% after the company sued U.S. health agencies to block Medicare price controls for Botox. The lawsuit argues Botox should be exempt from the Inflation Reduction Act’s negotiation program as a plasma-derived product. Investors are watching for early court developments and the Medicare timeline for 2028 prices. The case was assigned to U.S. District Judge Carl Nichols.
February 12, 2026
Amazon stock premarket: AMZN health-care push in focus as Wall Street weighs spending and CPI
···

Amazon stock premarket: AMZN health-care push in focus as Wall Street weighs spending and CPI

Amazon Pharmacy will expand same-day prescription delivery to 4,500 U.S. cities and towns by the end of 2026, adding nearly 2,000 communities, Reuters reported. Amazon shares closed down 1.4% at $204.08 ahead of Thursday trading. The company projected $200 billion in capital expenditures for 2026, up from $131 billion in 2025, mostly for AI infrastructure. Investors remain focused on spending and Friday’s inflation data.
February 12, 2026
Medtronic stock slips as earnings near, even after Needham upgrade flags new launches
···

Medtronic stock slips as earnings near, even after Needham upgrade flags new launches

Medtronic shares slipped 0.9% to $100.53 Wednesday afternoon, trailing gains in the S&P 500 ETF. The drop comes ahead of the company’s Feb. 17 fiscal Q3 results and management update. Needham upgraded the stock to “buy,” citing new product launches and activist involvement. Analyst price targets remain widely spread, with Needham’s at $121 and consensus near $106.
February 11, 2026
Elevance Health stock bounces as House subpoenas revive Obamacare subsidy scrutiny
···

Elevance Health stock bounces as House subpoenas revive Obamacare subsidy scrutiny

Elevance Health shares climbed 1.5% to $330.68 Wednesday after rebounding from an intraday low, as subpoenas from the House Judiciary Committee targeted the company and other insurers over ACA premium subsidies. Trading volume reached 0.67 million shares. Other major managed-care stocks mostly rose. RBC Capital Markets recently downgraded Elevance, citing a softer 2026 outlook and lower margin targets.
February 11, 2026
Abbott stock rises on AFib device data buzz as traders weigh FDA overhang
···

Abbott stock rises on AFib device data buzz as traders weigh FDA overhang

Abbott shares climbed 1.5% to $112.68 Tuesday, outperforming a flat healthcare sector as new atrial fibrillation device data drew investor attention. The company reported 93.9% complete closure at 45 days in its VERITAS study and 84.2% one-year freedom-from-recurrence with its Volt PFA system. Investors remain alert to fallout from Abbott’s recent diabetes sensor recall. Trading volume was near typical levels.
February 10, 2026
Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions
···

Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions

Novartis said AI reduced trial site selection for a 14,000-person Leqvio study to a two-hour meeting. Drugmakers report AI is cutting weeks from clinical trial logistics and regulatory paperwork. AstraZeneca and others still face challenges managing thousands of regulatory documents. Analysts say it may take one to three years before investors see the full impact on drug development timelines.
January 26, 2026
Yamanaka Factors Are Resetting Aging Cells
······

Rewinding the Clock: How Yamanaka Factors Are Resetting Aging Cells

In 2022, 124-week-old mice treated with inducible OSK via AAV9 and a 1-day-on/6-days-off cycle lived about twice as long in remaining lifespan, with a 9–12% median lifespan extension. Earlier studies showed partial reprogramming with OSKM extended lifespan and improved tissue function in mice. Human cell experiments reset aging markers by about 30 years. Safety concerns, including cancer risk, remain unresolved.
August 18, 2025
Senolytic Drugs
······

The Secret “Zombie Cell” Killers: Niche Senolytic Drugs Fighting Aging’s Clock

A Mayo Clinic-led Phase 2 trial published July 2024 found dasatinib plus quercetin modestly increased wrist bone density in older women with high senescent-cell burden. Unity Biotechnology’s foselutoclax improved vision in diabetic macular edema patients after a single injection. About 20 senolytic clinical trials are underway worldwide, with Alzheimer’s disease results expected in 2025.
August 17, 2025
How Engineering Nature’s Catalysts is Transforming Medicine, Food & the Planet
········

The Enzyme Revolution: How Engineering Nature’s Catalysts is Transforming Medicine, Food & the Planet

The global industrial enzyme market was valued at $9 billion in 2019 and is projected to reach $13.8 billion by 2027. Advances include the 2022 development of FAST-PETase, a machine-learning-designed enzyme that breaks down plastic waste in 24 hours, and a 2024 report of a highly evolved CRISPR-Cas enzyme variant with low off-target activity.
August 14, 2025
The Future of Artificial Blood, Organs, and Tissues - Breakthroughs and the Road to Transplantation
·······

In late 2022, UK researchers transfused lab-grown red blood cells into humans for the first time. The cost per unit dropped below $5,000 but remains higher than donated blood. In December 2024, the FDA approved Humacyte’s lab-grown blood vessel graft for trauma repair. Over 100,000 people in the U.S. await organ transplants; nearly 20 die daily.
August 13, 2025
How Gene Editing Therapies Are Curing the “Incurable”
·····

DNA Makeover: How Gene Editing Therapies Are Curing the “Incurable”

Casgevy became the first FDA-approved CRISPR-based therapy for sickle cell disease in late 2023, editing blood stem cells to boost fetal hemoglobin. Roctavian and Hemgenix, approved in 2023 and 2022, treat hemophilia A and B with single IV infusions that reduce bleeding and raise clotting factors. Zolgensma, approved in 2019 for spinal muscular atrophy, delivers a working gene in one dose.
August 12, 2025
Organ-on-a-Chip Technology
······

Lab Rats No More: How Organ-on-a-Chip Technology is Revolutionizing Drug Testing

The FDA announced in April 2025 it will phase out many animal tests within 3–5 years, starting with monoclonal antibody drugs. Columbia University linked four human organ tissues on a single chip, keeping them alive and communicating for weeks. A kidney-on-a-chip predicted drug toxicity missed by animal tests. The global organ-on-a-chip market is projected to reach nearly $1 billion by decade’s end.
August 10, 2025
The mRNA Revolution Transforming Medicine
····

Beyond COVID Vaccines: The mRNA Revolution Transforming Medicine

COVID-19 mRNA vaccines showed 94–95% efficacy in trials and over 13 billion doses were administered globally by 2022. In 2023, Moderna and Merck reported their personalized mRNA melanoma vaccine reduced recurrence or death by 44%. Moderna's RSV vaccine mRESVIA gained FDA approval in May 2024. The WHO set up an mRNA technology hub in South Africa in 2021, expanding to at least 15 countries by 2025.
August 10, 2025
Groundbreaking treatments - super crops - and a revolution in green technology
···

Biotech 2025: Breakthrough Cures, Super Crops, and a Green Tech Revolution

The global biotech market is set to rise from $483 billion in 2024 to $546 billion in 2025. Casgevy, the first CRISPR-based gene therapy for sickle cell disease, will reach patients in 2025. Novo Nordisk and Eli Lilly invested billions to resolve U.S. shortages of GLP-1 drugs. Over 60% of new crop varieties in 2025 use advanced gene-editing, not traditional breeding.
August 9, 2025
1 2 3 4 5

Stock Market Today

  • ASE Technology Holding Announces Strategic Collaboration with WUS Printed Circuit to Expand Semiconductor Manufacturing
    May 23, 2026, 8:28 AM EDT. ASE Technology Holding Co. (NYSE: ASX) on May 8 announced a strategic collaboration with WUS Printed Circuit Co. to build a new manufacturing facility in Kaohsiung, Taiwan. The facility will focus on advanced semiconductor packaging technologies like FOCoS and FCBGA targeting AI, cloud computing, and autonomous driving sectors. This expansion aims to boost Taiwan's role in the global semiconductor supply chain. ASE reported Q1 fiscal 2026 revenues of NT$173.7 billion, up 17.2% year-on-year but down 2.4% sequentially, with net income of NT$14.1 billion. The company provides integrated circuit packaging, engineering testing, and electronic manufacturing services. Investors should weigh ASE's growth against risks and alternatives in the semiconductor and AI stock space.